An even greater decrease in expression was observed in CD34+ cells from TKI-resistant CML patients (n = 3) exhibiting BCR::ABL1-independent resistance. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.